ArriVent Presents Proof-Of-Concept Phase 1b Data For Firmonertinib In EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer
Portfolio Pulse from Benzinga Newsdesk
ArriVent BioPharma, Inc. (NASDAQ: AVBP) will present interim Phase 1b data for firmonertinib, a treatment for EGFR PACC mutant non-small cell lung cancer, at the 2024 World Conference on Lung Cancer. The presentation will be part of the presidential session, and ArriVent will also host a virtual webinar on September 9, 2024.
August 12, 2024 | 12:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ArriVent BioPharma will present promising Phase 1b data for firmonertinib at a major conference, potentially boosting investor confidence and stock price.
The presentation of promising Phase 1b data at a prestigious conference could increase investor confidence in ArriVent's pipeline, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100